Bausch + Lomb Recalls enVista Intraocular Lenses Due to Inflammatory Complications

Bausch + Lomb (搜索)搜索该词条 has announced a voluntary recall of its entire enVista (搜索)搜索该药品 platform of intraocular lenses (搜索)搜索该药品 (IOLs) in the United States due to reports of post-surgical inflammatory complications. The recall affects all lots of multiple lens models used in cataract (搜索)搜索该疾病 surgery, including enVista Aspire (搜索)搜索该药品, enVista Aspire Toric, enVista Envy (搜索)搜索该药品, enVista Envy Toric, as well as enVista monofocal (搜索)搜索该药品 and enVista monofocal Toric lenses.

The company initiated the recall after receiving an increased number of reports of toxic anterior segment syndrome (搜索)搜索该疾病 (TASS (搜索)搜索该疾病), an acute sterile inflammatory reaction in the anterior chamber of the eye. TASS typically develops within 12 to 48 hours following cataract (搜索)搜索该疾病 surgery and can cause significant discomfort and potential complications if left untreated.

"As much as we believe in the enVista (搜索)搜索该药品 platform, patient safety will always be our number one priority," said Brent Saunders, chairman and CEO of Bausch + Lomb (搜索)搜索该词条, in a statement. "Surgeons and patients trust Bausch + Lomb, and I believe that this voluntary recall is the best thing we can do to honor that trust."

Understanding TASS and Its Impact

Toxic anterior segment syndrome (搜索)搜索该疾病 is a known potential complication of any cataract (搜索)搜索该疾病 surgery that can have various causes, including residual cleaning agents, bacterial endotoxins, or other contaminants introduced during the surgical procedure. The condition presents as inflammation inside the eye and requires prompt medical attention.

According to Bausch + Lomb (搜索)搜索该词条, all patients who developed TASS (搜索)搜索该疾病 in connection with the enVista (搜索)搜索该药品 lenses responded quickly to treatment, and none required removal of the implanted lenses. The company reports that the affected lenses represent only approximately 1-2 percent of all implanted enVista lenses, suggesting this is a relatively rare occurrence.

The company is currently investigating the root cause of these complications but decided to issue the recall as a precautionary measure while the investigation continues.

Recommendations for Patients and Healthcare Providers

Patients who have recently undergone cataract (搜索)搜索该疾病 surgery with enVista (搜索)搜索该药品 lenses should be vigilant for symptoms of TASS (搜索)搜索该疾病, which may include:

• Eye pain or discomfort
• Decreased vision
• Redness
• Light sensitivity

Bausch + Lomb (搜索)搜索该词条 advises patients experiencing any of these symptoms to contact their eye care professional immediately. For healthcare providers, the company recommends:

1. Closely monitoring cataract surgery patients for at least 48 hours post-procedure
2. Instructing patients to report any new or worsening symptoms immediately
3. Following established protocols for treating TASS if it occurs
4. Discontinuing use of all recalled enVista lenses

Cataract Surgery and Intraocular Lenses

Cataract (搜索)搜索该疾病 surgery is one of the most common surgical procedures performed worldwide, with approximately 4 million procedures conducted annually in the United States alone. During the procedure, the eye's cloudy natural lens is removed and replaced with an artificial intraocular lens.

The enVista (搜索)搜索该药品 platform includes several advanced IOL options designed to provide improved visual outcomes for patients undergoing cataract (搜索)搜索该疾病 surgery. These lenses are manufactured with specific features to address various visual needs, including astigmatism correction in the toric models.

Company Response and Future Plans

Despite the recall, Bausch + Lomb (搜索)搜索该词条 has expressed confidence in the overall safety profile of the enVista (搜索)搜索该药品 platform, noting that the vast majority of patients have experienced successful outcomes with these lenses.

"These reports represent an extremely small percentage of implanted lenses, with a positive prognosis for everyone involved," Saunders stated. "We look forward to identifying a root cause and bringing the enVista (搜索)搜索该药品 platform back to market."

The company has begun communicating with eye care professionals about the recall, providing information on affected lots and return protocols. Bausch + Lomb (搜索)搜索该词条 has not provided a timeline for when the enVista (搜索)搜索该药品 platform might return to the market, as this will depend on the findings of their ongoing investigation.

Industry Context

This recall comes at a time when the ophthalmic device market is highly competitive, with several major manufacturers offering advanced IOL technologies. Bausch + Lomb (搜索)搜索该词条, with its long history in eye care dating back to 1853, remains one of the leading global companies in the field with approximately 13,500 employees and operations in about 100 countries.

The company's prompt voluntary recall demonstrates the industry's commitment to patient safety, even when complications affect a relatively small percentage of devices. Such recalls, while disruptive in the short term, are essential to maintaining trust in medical devices and ensuring optimal patient outcomes.

Healthcare providers with questions about the recall can contact Bausch + Lomb (搜索)搜索该词条 directly or visit the FDA's recall notification page for additional information.